Locoregional therapy patterns and healthcare economic burden of patients with hepatocellular carcinoma in the USA.

IF 1.2 Q4 ONCOLOGY Hepatic Oncology Pub Date : 2021-04-21 eCollection Date: 2021-09-01 DOI:10.2217/hep-2021-0001

Abdalla Aly, Melissa Lingohr-Smith, Jay Lin, Brian Seal

引用次数: 0

Abstract

Aim: To examine the locoregional therapy (LRT) patterns and the healthcare economic burden of patients with hepatocellular carcinoma (HCC) in the USA.

Patients & methods: Patients with newly diagnosed HCC were identified from the MarketScan^® databases (1 July 2015-31 May 2018). The LRTs received and all-cause and HCC-related healthcare costs were measured.

Results: Among 2101 patients with HCC, most received embolization therapy as their first LRT treatment (57.8%, n = 1215); 17.1% (n = 360) received ablative therapy and 8.7% (n = 182) radiation therapy; 16.4% (n = 344) received multiple LRTs. After patients received their first LRT treatment, total all-cause healthcare costs averaged $20,316 per patient per month; 70.7% ($14,359) were HCC related.

Conclusion: Among newly diagnosed HCC patients treated with LRT in the USA, the economic burden is high.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

美国肝细胞癌患者的局部治疗模式和医疗经济负担

目的:探讨美国肝细胞癌(HCC)患者的局部区域治疗(LRT)模式和医疗经济负担。患者和方法:从MarketScan®数据库(2015年7月1日- 2018年5月31日)中确定新诊断的HCC患者。接受的lrt和全因和hcc相关的医疗费用被测量。结果:在2101例HCC患者中，大多数接受栓塞治疗作为首次LRT治疗(57.8%，n = 1215);17.1% (n = 360)接受消融治疗，8.7% (n = 182)接受放射治疗;16.4% (n = 344)接受了多重lrt。在患者接受第一次LRT治疗后，每位患者每月的全因医疗费用平均为20,316美元;70.7%(14359美元)与HCC相关。结论:在美国接受LRT治疗的新诊断HCC患者中，经济负担较高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.